Targovax ASA logo

TRVX - Targovax ASA News Story

NOK8.05 0.4  4.6%

Last Trade - 3:25pm

Sector
Healthcare
Size
Micro Cap
Market Cap £49.3m
Enterprise Value £46.2m
Revenue £238k
Position in Universe 989th / 1784

BRIEF-Targovax: TG02 Passes Initial Safety Review In First-In-Man Clinical Trial In Colorectal Cancer

Mon 18th December, 2017 6:01am
Dec 18 (Reuters) - Targovax ASA  TRVX.OL : 
    * REG-TARGOVAX ANNOUNCES THAT TG02 HAS PASSED THE INITIAL 
SAFETY 
REVIEW IN THE FIRST-IN-MAN CLINICAL TRIAL IN COLORECTAL CANCER 
 
Source text for Eikon:  ID:nGNE3QYWTM  
Further company coverage:  TRVX.OL  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.